Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems
Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.
You may also be interested in...
Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer
Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data from other ongoing trials will be needed to support filings amid looming competition from Opdivo.
What Late-Breakers To Look Out For At ASCO 2019
Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.
Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant disease.